Targeting amino acid metabolism in cancer growth and anti-tumor immune response

10.1186/2049-3002-1-5

10.1111/j.1365-2567.2012.03583.x

Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 2005;5:844-852.

10.1093/jnci/93.4.266

10.1007/s12026-012-8349-8

10.1126/science.123.3191.309

10.1038/nrc3038

10.1002/eji.200324048

Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB. The CD28 signaling pathway regulates glucose metabolism. Immunity 2002;16:769-777.

10.1016/0014-4827(73)90561-2

10.1126/science.1160809

10.1126/science.1188015

Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56:1164-1167.

Avramis VI. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res 2012;32:2423-2437.

10.1038/ng.890

10.1038/nm.3217

10.1038/cddis.2011.123

10.1042/bj3360001

Rose WC, Haines WJ, Warner DT. The amino acid requirements of man. V. The rôle of lysine, arginine, and tryptophan. J Biol Chem 1954;206:421-430.

10.1177/0148607186010002227

10.1002/cncr.20057

10.1158/1535-7163.MCT-09-0774

10.1158/0008-5472.CAN-13-1702

10.1007/s12307-011-0091-6

10.4143/crt.2013.45.4.251

Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003;24:302-306.

10.4049/jimmunol.170.1.270

Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998;160:5729-5734.

Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003;18:605-617.

10.1200/JCO.2004.11.120

10.1007/s10637-012-9807-9

10.1111/j.1600-065X.2010.00915.x

10.1038/nri1457

Mellor AL, Munn DH. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003;170:5809-5813.

Mellor AL, Munn D, Chandler P, Keskin D, Johnson T, Marshall B, Jhaver K, Baban B. Tryptophan catabolism and T cell responses. Adv Exp Med Biol 2003;527:27-35.

10.1097/CCO.0000000000000035

Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Göbel G. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12:1144-1151.

10.1016/j.ygyno.2009.07.015

10.1158/1078-0432.CCR-11-1331

Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-473.

10.1093/cvr/cvv100

10.1165/rcmb.2003-0268OC

Sakurai K, Zou JP, Torres NI, Tschetter JR, Kim HS, Shearer GM. Study of the effect of indoleamine 2,3-dioxygenase on murine mixed lymphocyte reactions and skin allograft rejection. Transplant Proc 2002;34:3271-3273.

10.1016/j.trim.2015.05.003

10.1038/nm934

10.1002/ijc.10645

10.1172/JCI21583

10.1158/1078-0432.CCR-07-4144

10.1158/0008-5472.CAN-12-0569

10.1073/pnas.1113873109

10.1084/jem.20120408

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801.

10.1016/j.bbapap.2011.07.023

10.3389/fimmu.2014.00673

10.1042/bj2450609

10.1042/bj1900451

10.1007/BF01659328

10.1016/0304-4165(85)90149-7

10.1042/bj2330617

10.1016/j.tibs.2014.02.004

10.1016/j.cmet.2011.08.004

10.1007/s10549-010-0848-5

10.1038/nature10350

10.1128/MCB.22.16.5793-5800.2002

10.1016/j.cell.2012.03.003

10.1016/j.coi.2014.01.006

10.1038/nrc3557

10.1038/nature11743

10.1016/j.cmet.2013.01.012

Mider GB. Some aspects of nitrogen and energy metabolism in cancerous subjects: a review. Cancer Res 1951;11:821-829.

10.1016/0020-711X(90)90001-J

10.1042/bj2120835

10.1042/bj2310713

10.1042/bj2280353

Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev 1990;48:297-309.

10.1016/j.tibs.2010.05.003

10.1073/pnas.1001006107

10.1073/pnas.0810199105

Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther 1990;46:243-271.

Ovejera AA, Houchens DP, Catane R, Sheridan MA, Muggia FM. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res 1979;39:3220-3224.

Griffiths M, Keast D, Patrick G, Crawford M, Palmer TN. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro. Int J Biochem 1993;25:1749-1755.

10.1186/bcr2154

Hutson SM, Sweatt AJ, Lanoue KF. Branched-chain [corrected] amino acid metabolism: implications for establishing safe intakes. J Nutr 2005;135:1557S-1564S.

Garber AJ, Karl IE, Kipnis DM. Alanine and glutamine synthesis and release from skeletal muscle. II. The precursor role of amino acids in alanine and glutamine synthesis. J Biol Chem 1976;251:836-843.

10.1016/j.cell.2008.11.044

10.1152/ajpendo.90645.2008

10.1242/jcs.051011

10.1111/j.1600-065X.2012.01152.x

10.4049/jimmunol.0803510

10.1074/jbc.M114.554113

10.4103/0971-5851.76197

10.1186/1476-4598-12-53

Yoshikawa R, Yanagi H, Shen CS, Fujiwara Y, Noda M, Yagyu T, Gega M, Oshima T, Yamamura T, Okamura H. ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J Gastroenterol 2006;12:5884-5889.

10.1200/JCO.2009.26.7765

10.1038/sj.bjc.6605856

10.1007/s10637-012-9862-2

Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23:7660-7668.

Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol 2011;4:138-146.

Jackson E, Minton SE, Ismail-Khan R, Han H, Neuger A, Antonia S, Sullivan D, Soliman HH. A phase I study of 1-methyl-d-tryptophan in combination with docetaxel in metastatic solid tumors. J Clin Oncol 2012;30 Suppl:abstrTPS2620.

Soliman HH, Antonia S, Sullivan D, Vanahanian N, Link C. Overcoming tumor antigen anergy in human malignancies using the novel indeolamine2,3- dioxygenase(IDO) enzyme inhibitor, 1-methyl-d-tryptophan(1MT). J Clin Oncol 2009;27:abstr3004.

10.1084/jem.20130066

10.1371/journal.pgen.1002573

Olver IN, Green M, Millward MJ, Bishop JF. Phase II study of acivicin in patients with recurrent high grade astrocytoma. J Clin Neurosci 1998;5:46-48.